Digital infrastructure company Equinix (EQIX) has completed the acquisition of MainOne, which provides data center and connectivity solutions in West Africa, at an enterprise value of $320 million. EQIX shares have climbed 8.7% over the past month.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The move bolsters Equinix’s strategy to become a major carrier-neutral digital infrastructure company in Africa that will provide a full range of technologies and connectivity in Nigeria, Ghana, and Cote d’Ivoire.
MainOne currently has three operational data centers and an additional facility is expected to begin operations in Lagos in April 2022. Recently, Equinix has also announced acquisitions in key geographies of South America, Canada, and India.
Hedge Fund Activity
TipRanks data points that Wall Street’s top hedge funds have decreased holdings in Equinix by 98,600 shares in the last quarter, indicating a very negative hedge fund confidence signal in the stock based on activities of 14 hedge funds.
Valuation Speaks
Now let’s have a look at some of the key metrics for Equinix and how it fares against the broader industry. The company’s earnings before interest, taxes, depreciation and amortization (EBITDA) margin of 38.5% lags the industry median of 56.2%, implying that Equinix has legroom to streamline its costs. Additionally, a forward non-GAAP P/E multiple of 107.4 indicates the share price of the company is expensive, compared to the industry median multiple of 46.2.
Further, a return on common equity of 4.6% implies Equinix is less efficient at putting its funds to work than the broader industry, where the median figure is 5.3%.
Download the TipRanks mobile app now
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Read full Disclaimer & Disclosure
Related News:
High Tide Declines 3.1% on Acquisition Plans
Sanofi to List Drug Ingredients Business
Clovis Jumps 22.4% on Positive Data for Rubraca